Meeting
2013 ASCO Annual Meeting
Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients.
Authors
Siraj M. Ali
Foundation Medicine, Inc., Cambridge, MA
Siraj M. Ali , Norma Alonzo Palma , Kai Wang , Jeffrey S. Ross , Philip J. Stephens , Roman Yelensky , Gary A. Palmer , Doron Lipson , Vincent A. Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8020)
DOI
10.1200/jco.2013.31.15_suppl.8020
Abstract #
8020
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.
First Author: Lindsay Carol Overton
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2014 Gastrointestinal Cancers Symposium
Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
First Author: Rachna T. Shroff
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock